Emcure

Ref: EPL/CS/SE/0066/2026 **Date:** August 06, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Script Symbol: EMCURE	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001 Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Presentation on Unaudited Financial Results for the quarter ended June 30, 2026.

Please find enclosed the presentation on the Unaudited Financial Results for the quarter ended June 30, 2026.

The same is also available on the Company's website i.e., www.emcure.com.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

AMRUTA AMIT YANGALWAR
Digitally signed by AMRUTA AMIT YANGALWAR
Date: 2026.08.06 13:52:56 +05'30'

Amruta Yangalwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Emcure

Results

Q1FY27

Aug 06, 2026

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute *"forward-looking statements."* These statements are based on Emcure Pharmaceuticals Limited's current expectations, assumptions, and projections about future events. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.

Such statements may include, but are not limited to, references to Emcure's business strategy, expansion plans, R&D pipeline, regulatory developments, financial performance, operational efficiencies, market conditions, and other future events. Words such as *"expects," "anticipates," "intends," "plans," "believes," "may," "will," "should,"* and similar expressions are intended to identify forward-looking statements.

These risks and uncertainties include regulatory changes, competitive pressures, technology changes, supply chain challenges, currency fluctuations, ability to obtain or maintain approvals, product commercialization timelines, and other risks inherent to the pharmaceutical industry.

This presentation is for general information only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, or subscribe to any securities of Emcure Pharmaceuticals Limited. Product information, including molecules under development or awaiting approval, is for representation purposes only. Availability of products may vary by geography depending on regulatory approvals and patent status. This presentation is not intended to provide medical advice.

The Company does not undertake to update or revise any forward-looking statements based on new information or future events.

Q1 FY27 – Corporate Updates

Emcure®

Mr. Satish Mehta to take over as Chairman, in addition to his existing role as Managing Director & CEO

(post the conclusion of the upcoming AGM)

Mr. Samit Mehta appointed COO of Emcure Pharmaceuticals

- Gets broader oversight of the Group’s R&D, operations and licensing activities.
- The elevation strengthens Emcure’s leadership and reinforces continuity in promoter-family stewardship

Gennova Biopharmaceuticals, now a wholly-owned subsidiary

- Mr. Samit Mehta to lead as CEO
- Will continue to anchor the Group's biologics and biosimilars capabilities
- Will complement Emcure's broader R&D and pipeline priorities

These steps strengthen the institutional depth required to deliver our five-year plan and create enduring value over the long term

Q1 FY27 - Key Financial Snapshot

Emcure

Revenue / Growth	EBITDA / Margin	PAT / Margin
25,804 / 22.8%	5,080 / 19.7% ▲ 50 bps	2,925 / 11.3% ▲ 110 bps
Revenue (INR Mn) / YoY growth	*EBITDA (INR Mn) / Margin*	*PAT (INR Mn) / Margin*

Segment Revenue Mix – Q1FY27

Domestic — 42%	International — 58%		
42%	20%	21%	17%
India	RoW	EU	CA

Key Highlights – Q1FY27

- Strong all-round performance with increased contribution from the International business (58%)
- International Business revenue up 34.2% YoY with strong growth across Europe, RoW and Canada
- Domestic revenue growth at 10.2%, reflecting a resilient performance
- Productivity gains and operating leverage help improve EBITDA margin by 50 bps
- PAT margin up 110 bps, at 11.3% - underline the strength of the quarter's operating performance.

Emcure

Q1FY27 – Other Financial Data Points

R&D (INR Mn)



RoCE[1]



CAPEX (INR Mn)



Net debt (INR Mn)



[1]RoCE refers to Return on Capital Employed, and is calculated by dividing EBIT for a given year by Capital Employed (i.e., total equity plus Net Debt) as of the end of that year; [2]TTM: Trailing twelve months

Emcure®

Q1 FY27 – Domestic Business Performance

Domestic (INR Mn)



Key Highlights

- Performance in line with expectations, supported by normalized Zuventus performance.
- Growth across CNS, women's health franchise and cardio-metabolics range led by key brands like Tenectase, Orofer XT, Orofer FCM, Metpure, etc. and supported by the Sanofi OAD and Roche portfolio
- Improved share of chronic segment
- Continue to build Poviztra® uptake; recent MASH[1] indication to help expand beyond traditional cardio-metabolics franchise
- Continued productivity enhancement reflected in increasing PCPM

Expect continued growth over the full year as our strengthened team and portfolio gain traction

[1]*MASH– Metabolic dysfunction-associated steatohepatitis*

Q1 FY27 – International Business Performance

Emcure

Europe (INR Mn)



- Strong EU and steady U.K. performance led by continued base business execution
- Liposomal Amphotericin B contribution continues to grow
- Product pipeline provides continued visibility for sustained growth over the medium term

Canada (INR Mn)



- Healthy growth through market share gains and new launches
- Growth balanced in both Quebec and rest of the Canada markets
- Received one product approval and launched two new products

RoW (INR Mn)



ARV[1]

- Strong orderbook led performance
- Signed a royalty-free, non-exclusive voluntary licensing agreement with MSD for **alimatravir**, a once-monthly oral PrEP[2] candidate, currently in late-stage development

Non-ARV[1]

- Scaling up of in-house developed portfolio across key markets
- 15+ products approved across Asia, Africa and LATAM in Q1 FY27; expanded into 3 new territories

A well diversified international platform driven by sustained business performance across both the base business and new business opportunities

[1]*ARV – Anti retroviral* , [2] PrEP - Pre-exposure prophylaxis

Emcure

P&L Summary | Q1 FY27

INR Mn except %	Q1 FY27	Q1 FY26	YoY %	Q4 FY26	QoQ %	FY26
Revenue from Operations	**25,804**	**21,005**	***22.8%***	**24,697**	***4.5%***	**92,035**
Domestic	10,953	9,935	*10.2%*	9,772	*12.1%*	40,270
International	14,851	11,070	*34.2%*	14,925	*-0.5%*	51,766
RoW	5,218	3,603	*44.8%*	5,557	*-6.1%*	18,399
EU	5,367	4,042	*32.8%*	5,376	*-0.2%*	18,498
CA	4,266	3,425	*24.6%*	3,992	*6.9%*	14,869
Gross Profit	**15,073**	**12,985**	***16.1%***	**14,666**	***2.8%***	**55,465**
Gross Profit Margin	*58.4%*	*61.8%*	***340bps***	*59.4%*	***100bps***	*60.3%*
EBITDA	**5,080**	**4,039**	***25.8%***	**4,855**	***4.6%***	**17,886**
EBITDA Margin	*19.7%*	*19.2%*	***50bps***	*19.7%*	-	*19.4%*
Profit Before Tax (PBT)	**3,935**	**2,908**	***35.3%***	**3,412**	***15.3%***	**12,871**
Effective Tax Rate (%)	*25.7%*	*26.1%*		*28.6%*		*26.9%*
Profit After Tax (PAT)	**2,925**	**2,148**	***36.2%***	**2,437**	***20.0%***	**9,413**
PAT Margin	*11.3%*	*10.2%*	***110bps***	*9.9%*	***140bps***	*10.2%*
Adjusted Profit After Tax (PAT)[1]	**2,909**	**2,174**	***33.8%***	**2,789**	***4.3%***	**10,075**
Adjusted PAT Margin	*11.3%*	*10.3%*	***100bps***	*11.3%*	-	*10.9%*

[1] *Exceptional item, impact of labour code, Changes in fair value of contingent consideration*

Emcure

For further information / institutional investor queries

Contact: Saurabh Paliwal
Email: Investor.Relations@emcure.com

Q1 FY27 CONFERENCE CALL DETAILS

Date: Thursday, August 6, 2026
Time: 04:00 pm IST
To Register: Click here to register

Registered Office

Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra, India

Website www.emcure.com